# US 2026/0098097 A1 · Immunotoxin-based targeted therapy for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098097 A1
- Document ID: US20260098097A1
- Status: Published application
- Kind: A1
- Application number: 19/140,326
- Filed: 2023-12-29
- Published: 2026-04-09
- Earliest claimed: 2022-12-30
- Assignees: The Regents of the University of Colorado, a body corporate
- Applicants: The Regents of the University of Colorado, a Body Corporate
- Inventors: Zhirui Wang; Zhaohui Wang; Bradley Haverkos
- Web page: https://patentgrep.com/patent/US20260098097A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 47/6829: {Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 14/55: IL-2
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C07K 2319/75: containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating various types of cancer, including cutaneous T-cell lymphoma, involve administering a therapeutically effective amount of a pharmaceutical composition containing a genetically engineered C-C motif chemokine receptor 4 bispecific immunotoxin, alone, or in combination with one or more additional therapeutic agents, such as a pharmaceutical composition containing an antibody-drug conjugate.

## Claims

### Claim 1

A method of treating or alleviating at least one symptom of cutaneous T-cell lymphoma in a subject, comprising:
administering to the subject a therapeutically effective amount of a genetically engineered C-C motif chemokine receptor 4 bispecific immunotoxin (“CCR4-IL2 bispecific immunotoxin”) and a therapeutically effective amount of an anti-CD30 antibody-drug conjugate.

### Claim 2 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the CCR4-IL2 bispecific immunotoxin is administered via a first pharmaceutical composition.

### Claim 3 (depends on 2)

The method of claim 2, wherein the therapeutically effective amount of the anti-CD30 antibody-drug conjugate is administered via a second pharmaceutical composition.

### Claim 4 (depends on 3)

The method of claim 3, wherein the first pharmaceutical composition and the second pharmaceutical composition are administered concurrently.

### Claim 5 (depends on 3)

The method of claim 3, wherein the first pharmaceutical composition and the second pharmaceutical composition are administered sequentially.

### Claim 6 (depends on 3)

The method of claim 3, wherein the first pharmaceutical composition is administered at a higher dose than the second pharmaceutical composition.

### Claim 7 (depends on 1)

The method of claim 1, wherein the genetically engineered CCR4-IL2 bispecific immunotoxin comprises an anti-human CCR4 scFv fused to a truncated diphtheria toxin DT390.

### Claim 8 (depends on 7)

The method of claim 7, wherein the genetically engineered CCR4-IL2 bispecific immunotoxin comprises a human IL2 peptide domain.

### Claim 9 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the genetically engineered CCR4-IL2 bispecific immunotoxin and the therapeutically effective amount of the anti-CD30 antibody-drug conjugate is administered via a pharmaceutical composition.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cutaneous T-cell lymphoma comprises CCR4+ and CD25+ cutaneous T-cell lymphoma.

### Claim 11 (depends on 1)

The method of claim 1, wherein the genetically engineered CCR4-IL2 bispecific immunotoxin reduces an amount of tumor-infiltrating Treg cells in the subject.

### Claim 12 (depends on 1)

The method of claim 1, wherein the CCR4-IL2 bispecific immunotoxin and the anti-CD30 antibody-drug conjugate are administered intravenously.

### Claim 13 (depends on 1)

The method of claim 1, further comprising performing a biopsy on a tumor within the subject.

### Claim 14 (depends on 1)

The method of claim 1, wherein administering the CCR4-IL2 bispecific immunotoxin and the anti-CD30 antibody-drug conjugate causes a reduction in one or more of a tumor volume, tumor weight, tumor number, or tumor metastasis.

### Claim 15

A system for treating or alleviating at least one symptom of cutaneous T-cell lymphoma in a subject diagnosed with cutaneous T-cell lymphoma, the system comprising:
at least one injection device configured to administer to the subject a therapeutically effective amount of a first pharmaceutical composition comprising a genetically engineered CCR4-IL2 bispecific immunotoxin and a therapeutically effective amount of a second pharmaceutical composition comprising an anti-CD30 antibody-drug conjugate.

### Claim 16 (depends on 15)

The system of claim 15, wherein the genetically engineered CCR4-IL2 bispecific immunotoxin comprises an anti-human CCR4 scFv fused to a truncated diphtheria toxin DT390.

### Claim 17 (depends on 16)

The system of claim 16, wherein the genetically engineered CCR4-IL2 bispecific immunotoxin comprises a human IL2 peptide domain.

### Claim 18 (depends on 15)

The system of claim 15, wherein an amino acid sequence of the genetically engineered CCR4-IL2 bispecific immunotoxin is at least 90% identical to SEQ ID NO: 2.

### Claim 19 (depends on 15)

The system of claim 15, wherein the first pharmaceutical composition is administered at a higher dose than the second pharmaceutical composition.

### Claim 20 (depends on 15)

The system of claim 15, wherein the at least one injection device comprises an intravenous injection device.
